Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience | Zendy

Giovanni Lo Re | Zendy; Davide Adriano Santeufemia | Zendy; Luisa Foltran | Zendy; Ettore Bidoli | Zendy; S.M.M. Basso | Zendy; Franco Lumachi | Zendy

Open Access

Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience

Author(s) -

Giovanni Lo Re,

Davide Adriano Santeufemia,

Luisa Foltran,

Ettore Bidoli,

S.M.M. Basso,

Franco Lumachi

Publication year - 2015

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.3143

Subject(s) - gemcitabine , medicine , regimen , pancreatic cancer , population , oncology , cancer , surgery , environmental health

The objectives of this study were to evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NAB-P/GEM) regimen in an unselected population of patients with advanced inoperable or metastatic pancreatic cancer (PC), and to identify the prognostic factors influencing overall survival (OS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research